1. ErbB Receptors as Prognostic and Therapeutic Drug Targets in Bone and Soft Tissue Sarcomas
- Author
-
Zhengdong Cai, Dongqing Zuo, Zeze Fu, Qingbo Yang, Hongsheng Wang, and Yingqi Hua
- Subjects
Drug ,Cancer Research ,Pathology ,medicine.medical_specialty ,animal structures ,medicine.medical_treatment ,media_common.quotation_subject ,Antineoplastic Agents ,Molecular evidence ,Biology ,Targeted therapy ,ErbB Receptors ,ErbB ,Biomarkers, Tumor ,medicine ,Humans ,Molecular Targeted Therapy ,Cancer biology ,skin and connective tissue diseases ,neoplasms ,media_common ,Clinical Trials as Topic ,ERBB Family ,Soft tissue ,Sarcoma ,General Medicine ,Oncology ,Cancer research - Abstract
ErbB receptors have been intensely studied to understand their importance in cancer biology and as therapeutic targets, and many ErbB inhibitors are now used in the clinical setting. A large number of studies have been conducted to examine the expression of ErbB family members in bone and soft tissue sarcomas, including osteosarcomas, synovial sarcomas, Ewing sarcomas, rhabdomyosarcomas, and so on. Nevertheless, the clinical implications of ErbB receptors remain elusive. To illustrate the potential of ErbB family members as prognostic and therapeutic drug targets in bone and soft tissue sarcomas, we summarized the molecular evidence and observations from clinical and basic trials.
- Published
- 2014
- Full Text
- View/download PDF